{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"43.5","value":"154"},{"groupId":"OG002","spread":"26.8","value":"106"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"Cycle 1, NSCLC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"51.9","value":"169"},{"groupId":"OG002","spread":"30.8","value":"137"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"title":"Cycle 3, NSCLC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.9","value":"115"},{"groupId":"OG002","spread":"36.7","value":"102"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"21"}],"units":"Participants"}],"title":"Cycle 1, melanoma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32","value":"171"},{"groupId":"OG002","spread":"52.8","value":"163"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"title":"Cycle 3, melanoma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.7","value":"118"},{"groupId":"OG002","spread":"28.3","value":"111"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"Cycle 1, RCC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"45.4","value":"158"},{"groupId":"OG002","spread":"43.5","value":"153"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"title":"Cycle 3, RCC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31","value":"116"},{"groupId":"OG002","spread":"37.6","value":"119"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"title":"Cycle 1, mesothelioma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.7","value":"141"},{"groupId":"OG002","spread":"33.1","value":"138"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"title":"Cycle 3, mesothelioma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.4","value":"144"},{"groupId":"OG001","spread":"53.1","value":"207"},{"groupId":"OG002","spread":"26.7","value":"132"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"13"}],"units":"Participants"}],"title":"Cycle 1, TNBC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"65.2","value":"179"},{"groupId":"OG001","spread":"55","value":"190"},{"groupId":"OG002","spread":"33.2","value":"157"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"Cycle 3, TNBC patients"}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"92"}],"units":"Participants"}],"description":"Pharmacokinetic (PK) parameters were calculated based on LAG525 serum concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed serum concentration following a dose.","dispersionType":"Standard Deviation","groups":[{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients naïve to anti-PD-1/PD-L1","id":"OG000","title":"Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 600 mg + PDR001 400 mg (Q4W/Q4W) in patients naïve to anti-PD-1/PD-L1","id":"OG001","title":"Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients pre-treated with anti-PD-1/PD-L1","id":"OG002","title":"Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W"}],"paramType":"MEAN","populationDescription":"All patients in phase 2 who received at least one full or partial dose of LAG525 and who had at least one serum sample providing evaluable PK data.","reportingStatus":"POSTED","timeFrame":"pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).","title":"Phase 2: Maximum Observed Serum Concentration (Cmax) of LAG525","type":"SECONDARY","unitOfMeasure":"ug/mL"}